Jonathan Goodman, MPhil

Researchers sought to determine whether belantamab mafodotin would be a viable option for treating patients with relapsed/refractory multiple myeloma

Researchers sought to determine whether adding daratumumab to lenalidomide and dexamethasone would improve outcomes in patients with newly diagnosed, transplant-ineligible MM.

Patients who received gefitinib plus platinum chemotherapy had significantly longer PFS2 than patients who received gefitinib alone.

The incidence of distant-stage cervical cancer in the United States increased by 1.3% per year from 2001 to 2018.

Researchers sought to determine whether patients with multiple myeloma would have a survival benefit from bortezomib with melphalan.

Serum sodium levels in the lower end of the normal range are associated with inferior outcomes in metastatic renal cell carcinoma, a study suggests.

Researchers sought to determine whether the combination pola-R-CHP would be cost-effective for treating patients with previously untreated DLBCL.

Researchers sought to determine whether BMP4 levels would be predictive of outcomes in pediatric patients with B cell precursor acute lymphoblastic leukemia.

Results of the phase 3 ATLAS trial revealed a potential new standard of care, according to researchers.

Medulloblastoma survivors had an increased risk of long-term adverse outcomes.